These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38608442)

  • 1. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis.
    Yang P; Shen G; Zhang H; Zhang C; Li J; Zhao F; Li Z; Liu Z; Wang M; Zhao J; Zhao Y
    Int Immunopharmacol; 2024 May; 133():111961. PubMed ID: 38608442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
    Lin L; Yang F; Lin G; Chen X
    J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
    Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
    Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
    Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
    Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
    J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis.
    Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K
    Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer.
    Qi Y; Zhang W; Jiang R; Xu O; Kong X; Zhang L; Fang Y; Wang J; Wang J
    Front Pharmacol; 2022; 13():960323. PubMed ID: 36188589
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants.
    Wu Q; Wu C; Xie X
    J Immunother; 2023 Feb-Mar 01; 46(2):29-42. PubMed ID: 36378154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.